Wang Y, Li C, Gale RP, Wang W, et al. Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies. Leukemia 2026 Oct 28. doi: 10.1038/s41375-026-03185.
PMID: 42957753